Congress trades and big insider sales, sent the day they're filed. Free.
Open in TelegramOfficers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.
Kurtz George0B / 239S · 10 late239 trades$59.22M
Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 2 | Cline Christopher R.CHIEF FINANCIAL OFFICER |  TVTXTravere Therapeutics, Inc.Option exercise · 10b5-1 plan | M | $349K 20.0K sh |
| Sep 17, 2026 traded Sep 15, 2026 |
| 2 | Tighe BrettChief Financial Officer | OKTAOkta, Inc. Tax withholding | F | — 1,386 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 2 | Tighe BrettChief Financial Officer | OKTAOkta, Inc. Tax withholding | F | — 1,525 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 2 | Bicket JohnDirector, SEE REMARKS, 10% Owner | IOTSamsara Inc. Derivative conversion | C | — 305.0K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 2 | Tighe BrettChief Financial Officer | OKTAOkta, Inc. Tax withholding | F | — 1,818 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 2 | Tighe BrettChief Financial Officer | OKTAOkta, Inc. Option exercise | M | — 3,520 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 2 | Tighe BrettChief Financial Officer | OKTAOkta, Inc. Option exercise | M | — 3,873 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 1 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS |  TBPHTheravance Biopharma, Inc.Open-market sale · 10b5-1 plan | SELL | $113K 6,657 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 1 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | TBPHTheravance Biopharma, Inc. Open-market sale · 10b5-1 plan | SELL | $57K 3,329 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 1 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | TBPHTheravance Biopharma, Inc. Open-market sale · 10b5-1 plan | SELL | $57K 3,328 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 1 | Choudary Kiran KumarChief Financial Officer | RBRKRubrik, Inc. Tax withholding · 10b5-1 plan | F | $1.40M 14.0K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | How AntoinetteChief Accounting Officer | NXDRNextdoor Holdings, Inc. Derivative conversion · 10b5-1 plan | C | — 154.9K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Larson Keith DGeneral Counsel and Secretary |  VGVenture Global, Inc.Option exercise · 10b5-1 plan | M | $332K 395.0K sh | Sep 17, 2026 traded Sep 17, 2026 |
| 0 | Fordyce MarshallDirector, PRESIDENT AND CEO |  VERAVera Therapeutics, Inc.Option exercise · 10b5-1 plan | M | $54K 18.5K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | How AntoinetteChief Accounting Officer | NXDRNextdoor Holdings, Inc. Derivative conversion · 10b5-1 plan | C | — 154.9K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Cline Christopher R.CHIEF FINANCIAL OFFICER | TVTXTravere Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 20.0K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Holme TimothyCHIEF TECHNOLOGY OFFICER |  QSQuantumScape CorpDerivative conversion · 10b5-1 plan | C | — 22.5K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Larson Keith DGeneral Counsel and Secretary | VGVenture Global, Inc. Option exercise · 10b5-1 plan | M | — 395.0K sh | Sep 17, 2026 traded Sep 17, 2026 |
| 0 | Kenneweg JohnSVP, Sales & Product Marketing |  MASS908 Devices Inc.Option exercise · 10b5-1 plan | M | $5,047 5,257 sh | Sep 17, 2026 traded Sep 17, 2026 |
| 0 | Kenneweg JohnSVP, Sales & Product Marketing | MASS908 Devices Inc. Option exercise · 10b5-1 plan | M | — 21.4K sh | Sep 17, 2026 traded Sep 16, 2026 |
| 0 | Kenneweg JohnSVP, Sales & Product Marketing | MASS908 Devices Inc. Option exercise · 10b5-1 plan | M | — 1,000 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Hanson Scott McLeanDirector, Chief Technology Officer |  AMBQAmbiq Micro, Inc.Option exercise · 10b5-1 plan | M | $57K 7,000 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Larson Keith DGeneral Counsel and Secretary | VGVenture Global, Inc. Option exercise · 10b5-1 plan | M | — 239.3K sh | Sep 17, 2026 traded Sep 16, 2026 |
| 0 | Choudary Kiran KumarChief Financial Officer | RBRKRubrik, Inc. Derivative conversion · 10b5-1 plan | C | — 4,000 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Larson Keith DGeneral Counsel and Secretary | VGVenture Global, Inc. Option exercise · 10b5-1 plan | M | $131K 155.7K sh | Sep 17, 2026 traded Sep 16, 2026 |
| 0 | Choudary Kiran KumarChief Financial Officer | RBRKRubrik, Inc. Option exercise · 10b5-1 plan | M | — 4,000 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Larson Keith DGeneral Counsel and Secretary | VGVenture Global, Inc. Option exercise · 10b5-1 plan | M | — 155.7K sh | Sep 17, 2026 traded Sep 16, 2026 |
| 0 | Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | TVTXTravere Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $33K 1,625 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Holme TimothyCHIEF TECHNOLOGY OFFICER | QSQuantumScape Corp Derivative conversion · 10b5-1 plan | C | — 22.5K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | TVTXTravere Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $28K 1,250 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Fordyce MarshallDirector, PRESIDENT AND CEO | VERAVera Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 18.5K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Tariq MusaDirector | GHGuardant Health, Inc. Option exercise · 10b5-1 plan | M | — 249 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Kenneweg JohnSVP, Sales & Product Marketing | MASS908 Devices Inc. Option exercise · 10b5-1 plan | M | — 5,257 sh | Sep 17, 2026 traded Sep 17, 2026 |
| 0 | Hanson Scott McLeanDirector, Chief Technology Officer | AMBQAmbiq Micro, Inc. Option exercise · 10b5-1 plan | M | — 7,000 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | McClymont DonaldDirector, Chief Executive Officer |  INDIindie Semiconductor, Inc.Option exercise · 10b5-1 plan | M | — 50.0K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | McClymont DonaldDirector, Chief Executive Officer | INDIindie Semiconductor, Inc. Option exercise · 10b5-1 plan | M | — 50.0K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Holme TimothyCHIEF TECHNOLOGY OFFICER | QSQuantumScape Corp Derivative conversion · 10b5-1 plan | C | — 22.5K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Kenneweg JohnSVP, Sales & Product Marketing | MASS908 Devices Inc. Option exercise · 10b5-1 plan | M | $960 1,000 sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Holme TimothyCHIEF TECHNOLOGY OFFICER | QSQuantumScape Corp Derivative conversion · 10b5-1 plan | C | — 22.5K sh | Sep 17, 2026 traded Sep 15, 2026 |
| 0 | Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | TVTXTravere Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 2,500 sh | Sep 17, 2026 traded Sep 15, 2026 |
TSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 631 insiders$417K
DRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
MTDRMatador Resources CoNov 5 – Nov 99 insiders$642K
FERGFerguson Enterprises Inc. /DE/Oct 12 – Oct 167 insiders$7.38M
SYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
UPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M
ADUSAddus HomeCare CorpNov 6 – Nov 96 insiders$16.28M
ARQQArqit Quantum Inc.Oct 2 – Oct 136 insiders$369K